Venus Remedies Limited has received GMP accreditation from Malaysia's NPRA for its pre-filled syringe facility, enhancing its global business opportunities within the ASEAN region.

This certification, the first of its kind for the company, allows for expedited approvals in other member countries.

With a significant capacity to produce enoxaparin, Venus is well-positioned to capture the growing market, projected to reach $5.415 billion by 2030.